Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARROW: Pralsetinib in RET-altered solid tumors
NCT03037385Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2017
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of pralsetinib in non-small cell lung cancer (NSCLC), Medullary Thyroid Cancer (MTC), papillary thyroid cancer (PTC), colorectal cancer (CRC), solid tumor, sponsored by Roche. Started Mar 2017; status: completed.
02
Drugs
pralsetinib
03
Conditions
non-small cell lung cancer (NSCLC)Medullary Thyroid Cancer (MTC)papillary thyroid cancer (PTC)colorectal cancer (CRC)solid tumor
Beyond the preview
Go deeper on NCT03037385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03037385.